Page last updated: 2024-08-02 07:48:47
pridopidine
Description
pridopidine: a dopamine stabilizer; structure in first source [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 9795739 |
| CHEMBL ID | 596802 |
| SCHEMBL ID | 166748 |
| MeSH ID | M0464604 |
Synonyms (37)
| Synonym |
|---|
| acr-16 |
| acr16 |
| CHEMBL596802 , |
| pridopidine |
| 4-(3-methylsulfonylphenyl)-1-propylpiperidine |
| 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine |
| bdbm50308028 |
| 346688-38-8 |
| D09953 |
| pridopidine (usan/inn) |
| acr16 compound |
| pridopidine [usan:inn] |
| 4-(3-methanesulfonylphenyl)-1-propylpiperidine |
| unii-hd4tw8s2vk |
| acr 16 |
| piperidine, 4-(3-(methylsulfonyl)phenyl)-1-propyl- |
| 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine |
| 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine |
| hd4tw8s2vk , |
| FT-0672149 |
| AKOS015891431 |
| SCHEMBL166748 |
| pridopidine [inn] |
| pridopidine [usan] |
| pridopidine [who-dd] |
| pridopidine [mi] |
| DTXSID90188225 |
| NCGC00386586-01 |
| DB11947 |
| 4-3-(methylsulfonyl)phenyl-1-propylpiperidine |
| mfcd09835586 |
| AS-50146 |
| Q7242858 |
| HY-10684 |
| CS-0002733 |
| asp2314 |
| O11067 |
Protein Targets (3)
Potency Measurements
Inhibition Measurements
Bioassays (22)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID458641 | Reduction in spontaneous locomotor activity in Sprague-Dawley rat striatum at 100 umol/kg, sc relative to control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID458632 | Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID714095 | Reduction in spontaneous locomotor activity in Sprague-Dawley rat at 300 umol/kg, sc measured after 15 to 60 mins relative to saline-treated control | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804 | Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. |
| AID714104 | Increase in DOPAC level in sc dosed Sprague-Dawley rat striatum by HPLC analysis | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804 | Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. |
| AID458633 | Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID714098 | Decrease in 5-HIAA level in Sprague-Dawley rat striatum at 300 umol/kg, sc by HPLC analysis relative to saline-treated control | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804 | Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. |
| AID736003 | Displacement of [3H]Ro 41-1049 from rat MAO-A receptor expressed in HEK293 cells | 2013 | European journal of medicinal chemistry, Apr, Volume: 62ISSN: 1768-3254 | Synthesis, pharmacological evaluation and QSAR modeling of mono-substituted 4-phenylpiperidines and 4-phenylpiperazines. |
| AID458634 | Selectivity ratio of Ki for human dopamine D2 receptor at low affinity state to Ki for human dopamine D2 receptor at high affinity state | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID1718135 | Inhibition of [3H](+)-pentazocine binding to human sigma1 receptor expressed in HEK293 cells by liquid scintillation spectrometry | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
ISSN: 1520-4804 | Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. |
| AID1718170 | Binding affinity to dopamine D2 (high) receptor (unknown origin) | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
ISSN: 1520-4804 | Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. |
| AID1718169 | Binding affinity to dopamine D2 (low) receptor (unknown origin) | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
ISSN: 1520-4804 | Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. |
| AID458635 | Activity at dopamine D2L receptor expressed in HEK293 cells coexpressing Galphaqi5 assessed as maximal efficacy relative to control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID714099 | Increase in DOPAC level in Sprague-Dawley rat striatum at 300 umol/kg, sc by HPLC analysis relative to saline-treated control | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804 | Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. |
| AID714105 | Displacement of [3H]Ro 41-1049 from MAO-A in rat cerebral cortex by competition binding assay | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804 | Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. |
| AID714107 | Displacement of [3H]imipramine from human SERT expressed in CHO cells by competition binding assay | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804 | Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. |
| AID458636 | Reduction in 3,4-dihydroxyphenylacetic acid level in Sprague-Dawley rat striatum at 100 umol/kg, sc relative to saline treated control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID458654 | Reduction in amphetamine-induced locomotor activity in Sprague-Dawley rat striatum at 150 umol/kg, sc relative to control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
Research
Studies (67)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (8.96) | 29.6817 |
| 2010's | 46 (68.66) | 24.3611 |
| 2020's | 15 (22.39) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 12 (17.39%) | 5.53% |
| Reviews | 8 (11.59%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 49 (71.01%) | 84.16% |
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 3,4-dihydroxyphenylacetic acid | | catechols;
dihydroxyphenylacetic acid | human metabolite | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dihydroxyphenylalanine | | hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative | human metabolite | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| alpha-methyltyrosine methyl ester | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amphetamine | | primary amine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2004 | 2013 | 16.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| kinetin | | 6-aminopurines;
furans | cytokinin;
geroprotector | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxidopamine | | benzenetriol;
catecholamine;
primary amino compound | drug metabolite;
human metabolite;
neurotoxin | 2013 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2006 | 2011 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tetrabenazine | | benzoquinolizine;
cyclic ketone;
tertiary amino compound | | 2014 | 2018 | 7.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| carbostyril | | monohydroxyquinoline;
quinolone | bacterial xenobiotic metabolite | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylpiperazine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperidine | | azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine | base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methylaspartate | | amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound | neurotransmitter agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 4-phenylpiperidine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| a 68930 | | 2-benzopyran | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ferric ferricyanide | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzofurans | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| raclopride | | salicylamides | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sch 23390 | | benzazepine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vitamin k 1 | | phylloquinones;
vitamin K | cofactor;
human metabolite;
plant metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| preclamol | | | | 2004 | 2017 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dizocilpine maleate | | maleate salt;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 2004 | 2005 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| osu 6162 | | | | 2004 | 2013 | 15.6 | high | 0 | 0 | 0 | 6 | 2 | 0 |
| 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride | | | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ubiquinone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valbenazine | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperidines | | | | 2004 | 2022 | 8.9 | high | 10 | 0 | 0 | 12 | 41 | 7 |
| 2-phytyl-1,4-naphthoquinone | | phylloquinones | | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | | nucleoside triphosphate analogue | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine.Autophagy, , Volume: 19, Issue:1, 2023
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.The European journal of neuroscience, , Volume: 55, Issue:5, 2022
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1Cell death & disease, , 03-01, Volume: 10, Issue:3, 2019
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.JCI insight, , 12-07, Volume: 2, Issue:23, 2017
One-year safety and tolerability profile of pridopidine in patients with Huntington disease.Neurology, , Mar-19, Volume: 80, Issue:12, 2013
Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model.Neurobiology of disease, , 10-15, Volume: 173, 2022
The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 18, Issue:2, 2021
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [European journal of nuclear medicine and molecular imaging, , Volume: 48, Issue:4, 2021
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.Journal of Huntington's disease, , Volume: 9, Issue:4, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.Journal of Huntington's disease, , Volume: 9, Issue:2, 2020
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.The Lancet. Neurology, , Volume: 18, Issue:2, 2019
The hunt for better treatments for Huntington's disease.The Lancet. Neurology, , Volume: 18, Issue:2, 2019
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.Neurobiology of disease, , Volume: 129, 2019
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.Molecular neurodegeneration, , 05-21, Volume: 13, Issue:1, 2018
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.Journal of Huntington's disease, , Volume: 7, Issue:1, 2018
Improved metrics for Huntington's disease trials.Nature, , Volume: 557, Issue:7707, 2018
Antipsychotic drugs in Huntington's disease.Expert review of neurotherapeutics, , Volume: 17, Issue:3, 2017
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.Neurobiology of disease, , Volume: 97, Issue:Pt A, 2017
Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.British journal of clinical pharmacology, , Volume: 83, Issue:10, 2017
Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.CNS neuroscience & therapeutics, , Volume: 23, Issue:6, 2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.Journal of Huntington's disease, , Volume: 6, Issue:3, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.JCI insight, , 12-07, Volume: 2, Issue:23, 2017
The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.British journal of clinical pharmacology, , Volume: 81, Issue:2, 2016
Pridopidine for the treatment of Huntington's disease.Expert opinion on investigational drugs, , Volume: 25, Issue:4, 2016
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.Human molecular genetics, , 09-15, Volume: 25, Issue:18, 2016
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Journal of cellular and molecular medicine, , Volume: 19, Issue:11, 2015
Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Drug design, development and therapy, , Volume: 9, 2015
The pridopidine paradox in Huntington's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:10, 2013
One-year safety and tolerability profile of pridopidine in patients with Huntington disease.Neurology, , Mar-19, Volume: 80, Issue:12, 2013
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:10, 2013
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.The Lancet. Neurology, , Volume: 10, Issue:12, 2011
Pridopidine in treatment of Huntington's disease: beyond chorea?The Lancet. Neurology, , Volume: 10, Issue:12, 2011
HD Therapeutics - CHDI Fifth Annual Conference.IDrugs : the investigational drugs journal, , Volume: 13, Issue:4, 2010
Trial watch: NeuroSearch's dopaminergic stabilizer improves movement disorders in Huntington's disease.Nature reviews. Drug discovery, , Volume: 9, Issue:4, 2010
Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.Clinical neuropharmacology, , Volume: 34, Issue:3
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.Clinical neuropharmacology, , Volume: 33, Issue:5
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.The European journal of neuroscience, , Volume: 55, Issue:5, 2022
Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 19, Issue:5, 2022
Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders.Expert opinion on drug discovery, , Volume: 16, Issue:4, 2021
Pridopidine in the treatment of Huntington's disease.Reviews in the neurosciences, , May-26, Volume: 31, Issue:4, 2020
HD Therapeutics - CHDI Fifth Annual Conference.IDrugs : the investigational drugs journal, , Volume: 13, Issue:4, 2010
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.The European journal of neuroscience, , Volume: 55, Issue:5, 2022
Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 19, Issue:5, 2022
Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders.Expert opinion on drug discovery, , Volume: 16, Issue:4, 2021
Pridopidine in the treatment of Huntington's disease.Reviews in the neurosciences, , May-26, Volume: 31, Issue:4, 2020
HD Therapeutics - CHDI Fifth Annual Conference.IDrugs : the investigational drugs journal, , Volume: 13, Issue:4, 2010
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine.Autophagy, , Volume: 19, Issue:1, 2023
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.The European journal of neuroscience, , Volume: 55, Issue:5, 2022
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1Cell death & disease, , 03-01, Volume: 10, Issue:3, 2019
Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model.Neurobiology of disease, , 10-15, Volume: 173, 2022
Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 19, Issue:5, 2022
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.The European journal of neuroscience, , Volume: 55, Issue:5, 2022
Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders.Expert opinion on drug discovery, , Volume: 16, Issue:4, 2021
Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma.Scientific reports, , 11-09, Volume: 11, Issue:1, 2021
The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 18, Issue:2, 2021
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.Neurobiology of disease, , Volume: 124, 2019
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1Cell death & disease, , 03-01, Volume: 10, Issue:3, 2019
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.Neurobiology of disease, , Volume: 97, Issue:Pt A, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.JCI insight, , 12-07, Volume: 2, Issue:23, 2017
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.Human molecular genetics, , 09-15, Volume: 25, Issue:18, 2016
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Journal of cellular and molecular medicine, , Volume: 19, Issue:11, 2015
HD Therapeutics - CHDI Fifth Annual Conference.IDrugs : the investigational drugs journal, , Volume: 13, Issue:4, 2010
Schizophrenia: from dopamine to glutamate and back.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model.Neurobiology of disease, , 10-15, Volume: 173, 2022
The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 18, Issue:2, 2021
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [European journal of nuclear medicine and molecular imaging, , Volume: 48, Issue:4, 2021
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.Journal of Huntington's disease, , Volume: 9, Issue:4, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.Journal of Huntington's disease, , Volume: 9, Issue:2, 2020
The hunt for better treatments for Huntington's disease.The Lancet. Neurology, , Volume: 18, Issue:2, 2019
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.Neurobiology of disease, , Volume: 129, 2019
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.The Lancet. Neurology, , Volume: 18, Issue:2, 2019
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.Journal of Huntington's disease, , Volume: 7, Issue:1, 2018
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.Molecular neurodegeneration, , 05-21, Volume: 13, Issue:1, 2018
Improved metrics for Huntington's disease trials.Nature, , Volume: 557, Issue:7707, 2018
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.Neurobiology of disease, , Volume: 97, Issue:Pt A, 2017
Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.British journal of clinical pharmacology, , Volume: 83, Issue:10, 2017
Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.CNS neuroscience & therapeutics, , Volume: 23, Issue:6, 2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.Journal of Huntington's disease, , Volume: 6, Issue:3, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.JCI insight, , 12-07, Volume: 2, Issue:23, 2017
Antipsychotic drugs in Huntington's disease.Expert review of neurotherapeutics, , Volume: 17, Issue:3, 2017
The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.British journal of clinical pharmacology, , Volume: 81, Issue:2, 2016
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.Human molecular genetics, , 09-15, Volume: 25, Issue:18, 2016
Pridopidine for the treatment of Huntington's disease.Expert opinion on investigational drugs, , Volume: 25, Issue:4, 2016
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Journal of cellular and molecular medicine, , Volume: 19, Issue:11, 2015
Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Drug design, development and therapy, , Volume: 9, 2015
The pridopidine paradox in Huntington's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:10, 2013
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:10, 2013
One-year safety and tolerability profile of pridopidine in patients with Huntington disease.Neurology, , Mar-19, Volume: 80, Issue:12, 2013
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.The Lancet. Neurology, , Volume: 10, Issue:12, 2011
Pridopidine in treatment of Huntington's disease: beyond chorea?The Lancet. Neurology, , Volume: 10, Issue:12, 2011
HD Therapeutics - CHDI Fifth Annual Conference.IDrugs : the investigational drugs journal, , Volume: 13, Issue:4, 2010
Trial watch: NeuroSearch's dopaminergic stabilizer improves movement disorders in Huntington's disease.Nature reviews. Drug discovery, , Volume: 9, Issue:4, 2010
Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.Clinical neuropharmacology, , Volume: 34, Issue:3
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.Clinical neuropharmacology, , Volume: 33, Issue:5
Safety/Toxicity (6)
| Article | Year |
|---|
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
Journal of Huntington's disease, , Volume: 9, Issue:2 | 2020 |
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
Neurobiology of disease, , Volume: 129 | 2019 |
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
The Lancet. Neurology, , Volume: 18, Issue:2 | 2019 |
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
Journal of Huntington's disease, , Volume: 6, Issue:3 | 2017 |
One-year safety and tolerability profile of pridopidine in patients with Huntington disease.
Neurology, , Mar-19, Volume: 80, Issue:12 | 2013 |
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
Clinical neuropharmacology, , Volume: 33, Issue:5 | |
Pharmacokinetics (2)
Bioavailability (2)
Dosage (6)
| Article | Year |
|---|
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.
Journal of Huntington's disease, , Volume: 9, Issue:4 | 2020 |
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
Journal of Huntington's disease, , Volume: 9, Issue:2 | 2020 |
Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats.
Journal of Huntington's disease, , Volume: 3, Issue:3 | 2014 |
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:10 | 2013 |
Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
European journal of drug metabolism and pharmacokinetics, , Volume: 38, Issue:1 | 2013 |
The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.
European journal of clinical pharmacology, , Volume: 68, Issue:9 | 2012 |
Interactions (1)